50. 皮膚筋炎/多発性筋炎 Dermatomyositis Clinical trials / Disease details
臨床試験数 : 182 / 薬物数 : 229 - (DrugBank : 88) / 標的遺伝子数 : 48 - 標的パスウェイ数 : 147
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2018-000391-15-IT (EUCTR) | 05/06/2018 | 27/02/2018 | Multicentric, prospective open-label study to assess the efficacy and safety of Tocilizumab in subjects with refractory myositis | Multicentric, open-label, prospective study of subcutaneous tocilizumab in adult patients with refractory myositis - ToReMy | Myositis (dermatomyositis [DM] or polymyositis [PM]) MedDRA version: 20.0;Level: PT;Classification code 10012503;Term: Dermatomyositis;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders MedDRA version: 20.0;Classification code 10028653;Term: Myositis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders MedDRA version: 20.0;Classification code 10036102;Term: Polymyositis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] | Trade Name: RoActemra 162 mg soluzione iniettabile in siringa preriempita Product Name: RoActemra 162 mg soluzione iniettabile in siringa preriempita Product Code: NA INN or Proposed INN: Tocilizumab Other descriptive name: TOCILIZUMAB | Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia | NULL | Not Recruiting | Female: yes Male: yes | 16 | Phase 2 | Italy | ||
2 | NCT02043548 (ClinicalTrials.gov) | October 1, 2014 | 17/1/2014 | Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis | Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis | Dermatomyositis;Polymyositis | Drug: tocilizumab;Drug: placebo | Chester Oddis | Genentech, Inc. | Completed | 18 Years | N/A | All | 36 | Phase 2 | United States |